XOMA Royalty Corp (XOMA) Financial Ratio Screen
Follow screening changes
Email alerts are not currently available. Bookmark this page and check the financial period and retrieval date when reviewing a result.
MSCI new-inclusion financial-ratio snapshot
XOMA financial screening at a glance
Calculation date: 2026-10-16. Financial period used: December 2024. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.
Independent method comparison
What the available screens say
How MSCI, FTSE and S&P-style screens differThe request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.
Business activity evidence
Activity assessment in progress
The supplied classification (Biotechnology) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.
Revenue segments: Not yet checked against an SEC annual filing.
Profile description reviewed: XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings
A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.
Published-ratio reproductions (not certifications)
The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style debt and cash reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| MSCI | 53.9% / 30% | 47.5% / 30% | 53.6% / 30% | N/A | RATIOS FAIL* |
| FTSE | 53.9% / 33% | 47.5% / 33% | 53.6% / 50% | N/A | RATIOS FAIL* |
Financial Highlights
Profitability
| Gross Margin | 96.7% | |
| Operating Margin | 15.9% | |
| Net Margin | 60.8% | |
| Return on Equity (ROE) | 34.1% | |
| Return on Assets (ROA) | 2.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -14M (currency unverified) |
| Free Cash Flow | -14M (currency unverified) |
| Total Debt | 119M (currency unverified) |
| Debt-to-Equity | 126.5 |
| Current Ratio | 3.4 |
| Total Assets | 221M (currency unverified) |
Price & Trading
| Last Close | $30.53 |
| 50-Day MA | $26.41 |
| 200-Day MA | $29.76 |
| Avg Volume | 411K |
| Beta | 0.8 |
|
52-Week Range
$18.35
| |
Financial data provenance and verification
The displayed fields were imported from yfinance on 2026-03-29 for the financial period December 2024. This is a secondary data feed and can differ from amended or newly filed statements.
- Issuer website — use its investor-relations filings to verify the figures.
- SEC EDGAR filing search — primary filing source for US issuers.
- Field mapping, formulas and limitations.
Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.
About XOMA Royalty Corp (XOMA)
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Popular halal stock checks
Explore other frequently viewed automated stock screens and compare the available financial ratios.
Frequently Asked Questions
Is XOMA Royalty Corp (XOMA) halal to invest in?
The current automated result is Financial criteria not met or an activity exclusion was detected. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.
What is XOMA Royalty Corp's debt ratio?
XOMA Royalty Corp's debt ratio is 53.9% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.
What are XOMA Royalty Corp's key financial metrics?
XOMA Royalty Corp has a market capitalization of USD 359M in its listing currency, trailing P/E ratio of 20.7, and revenue of 10M (currency unverified). The company maintains a gross margin of 96.7% and a net margin of 60.8%. Return on equity stands at 34.1%.
How often is the screening data updated?
Calculation date: 2026-10-16. Financial period: December 2024. These dates are shown separately because regenerating this page does not refresh the underlying data.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.